International Programm: "Challenges in Targeted Therapies for Breast Cancer"
The goal of this two day programme is to provide an overview on state-of-the art targeted therapies in breast cancer and to enable participants to enable them to optimize tailored therapies in an environment of increasing economic pressures.
Participants should have a general knowledge of systemic antitumor therapies currently utilized for adjuvant and metastatic breast cancer. Upon completion of the course, they will have a thorough knowledge on the molecular and clinical basis of targeted therapies in breast cancer. Participants will also be able to balance the potential gains and costs of currently available antibody (Ab) and tyrosin-kinase inhibitor (TKI) - based regimen in order to provide optimal systemic breast cancer treatment.
? Understanding of therapy-related tumor biology of breast cancer
? Knowledge of the molecular basis of targeted therapies
? Knowledge of key clinical trials related to targeted therapies in breast cancer
? Knowledge of therapy-related side effects of antibody and TKI therapies
? Understanding of the cost-benefit and QALY-related parameters related to targeted therapies
? Ability to implement state-of-the art targeted therapies
The two-day programme is comprised of four core themes and will introduce participants to the biological and clinical aspects of targeted therapies in breast cancer. In addition to interactive lectures and case presentations, the course will also include group work and simulation exercises. A visit to selected clinical departments of MUV Medical Center, one of Europe´s premier educational institutions for research clinical excellence, will complete the Leadership Programme. All participants will receive a Certificate of Attendance, issued by MUVI.
» More information